Reactivation of mitotic arrest upon targeting TACC3 restores immunogenic cell death and T-DM1 response in HER2-positive breast cancer

被引：1
|
作者：
Saatci, Ozge
Gedik, Mustafa Emre
Oberholtzer, Nathaniel
Uner, Meral
Akbulut, Ozge
Cetin, Metin
Aras, Mertkaya
Ibis, Kubra
Caliskan, Burcu
Banoglu, Erden
Wiemann, Stefan
Uner, Aysegul
Aksoy, Sercan
Mehrotra, Shikhar
Sahin, Ozgur
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB275
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB275
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
    Peipei Liu
    Jiajun Fan
    Ziyu Wang
    Wenjing Zai
    Ping Song
    Yongping Li
    Dianwen Ju
    AMB Express, 10
  • [32] ERBB2mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
    Griguolo, Gaia
    Braso-Maristany, Fara
    Gonzalez-Farre, Blanca
    Pascual, Tomas
    Chic, Nuria
    Sauri, Tamara
    Kates, Ronald
    Gluz, Oleg
    Martinez, Debora
    Pare, Laia
    Tsvetkova, Vassilena
    Pesantez, David
    Vidal, Maria
    Adamo, Barbara
    Munoz, Montserrat
    Galvan, Patricia
    Barbera, Laura
    Cuatrecasas, Miriam
    Christgen, Mathias
    Kreipe, Hans
    Monge-Escartin, Ines
    Villagrasa, Patricia
    Soy, Dolors
    Giarratano, Tommaso
    Dieci, Maria Vittoria
    Conte, Pierfranco
    Harbeck, Nadia
    Guarneri, Valentina
    Prat, Aleix
    CANCERS, 2020, 12 (07) : 1 - 25
  • [33] In vitro effects of Trastuzumab Emtansine (T-DM1) and concurrent irradiation on HER2-positive breast cancer cells
    Mignot, F.
    Kirova, Y.
    Verrelle, P.
    Teulade-Fichou, M-P
    Megnin-Chanet, F.
    CANCER RADIOTHERAPIE, 2021, 25 (02): : 126 - 134
  • [34] Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy
    Molinelli, Chiara
    Parisi, Francesca
    Razeti, Maria Grazia
    Arecco, Luca
    Cosso, Maurizio
    Fregatti, Piero
    Del Mastro, Lucia
    Poggio, Francesca
    Lambertini, Matteo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (03) : 241 - 250
  • [35] The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
    Liu, Peipei
    Fan, Jiajun
    Wang, Ziyu
    Zai, Wenjing
    Song, Ping
    Li, Yongping
    Ju, Dianwen
    AMB EXPRESS, 2020, 10 (01)
  • [36] Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer
    Akyildiz, Arif
    Ismayilov, Rashad
    Abdurrahimli, Najmaddin
    Ormanci, Aylin
    Guven, Deniz Can
    Tuncel, Murat
    Onur, Mehmet Ruhi
    Aksoy, Sercan
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (02) : 100 - 105
  • [37] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    Jacot, William
    Pons, Elvire
    Frenel, Jean-Sebastien
    Guiu, Severine
    Levy, Christelle
    Heudel, Pierre Etienne
    Bachelot, Thomas
    D'Hondt, Veronique
    Darlix, Amelie
    Firmin, Nelly
    Romieu, Gilles
    Thezenas, Simon
    Dalenc, Florence
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (02) : 307 - 318
  • [38] STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer
    Wang, Lei
    Wang, Quanren
    Gao, Mingzhao
    Fu, Li
    Li, Yun
    Quan, Haitian
    Lou, Liguang
    CANCER SCIENCE, 2018, 109 (10): : 3305 - 3315
  • [39] Cost-effectiveness of trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer (ABC)
    Quang Anh Le
    Bae, Yuna
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer
    Ponde, Noam
    Ameye, Lieveke
    Lambertini, Matteo
    Paesmans, Marianne
    Piccart, Martine
    de Azambuja, Evandro
    EUROPEAN JOURNAL OF CANCER, 2020, 126 : 65 - 73
12345